In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, first-line trastuzumab deruxtecan (T-DXd; Enhertu) combined with pertuzumab ...

Trastuzumab deruxtecan-THP was associated with a statistically significant and clinically meaningful improvement in pathologic complete response rate vs standard of care. The DESTINY-Breast11 ...

Skin rashes were also reported with ... creating unwanted T-cell activation and tumor or healthy tissue toxicity,” she continued. To mitigate these AEs, the investigators proposed a co-treatment with ...

trastuzumab deruxtecan With regards to enfortumab vedotin, the most common toxicities are secondary to the MMAE payload. This includes skin toxicity through the delivery of MMAE into Nectin-4 ...

The drug can cause pulmonary toxicity in the ... patients for reactions like skin rash, shortness of breath, nausea, dizziness, low blood pressure. Store Trastuzumab in the refrigerator at 2 ...

Trastuzumab duocarmazine (T-Duo ... growth factor receptor 2–positive (HER2+) breast cancer. However, ocular toxicity was prevalent, leading to higher discontinuation rates in the experimental ...

Neratinib, fulvestrant, trastuzumab combo aids metastatic breast cancer Nov 29, 2023 Cancer trial discovers a potentially broader role for an established dual HER2-blocking treatment ...

In the phase 2 DESTINY-PanTumor01 trial, trastuzumab deruxtecan showed clinically meaningful ... the most common reason was objective disease progression (61.8%), followed by toxicity (61.8%), other ...

Short-duration trastuzumab did not show noninferiority ... treatment was also associated with significantly lower cardiac toxicity.” The Short-HER2 phase 3 trial compared short-duration (9 ...

Patients with early-stage, HER2-positive breast cancer who received both adjuvant ado-trastuzumab emtansine and concurrent ... Most experienced grade 2 skin dermatitis, although 1 patient developed ...

Among those painful side effects is skin toxicity induced by epidermal growth factor receptor (EGFR) inhibitors. The powerful therapy has become one of the best weapons against some of the most ...